Lungpacer Medical

Executive Summary

Lungpacer Medical is a privately held medical device company specializing in neurostimulation therapies for critical respiratory care. Its lead product, the AeroPace System, is a temporary transvenous diaphragm pacing system designed to accelerate weaning from mechanical ventilation in intensive care patients. By electrically stimulating the phrenic nerve to contract the diaphragm, the device aims to prevent respiratory muscle atrophy, reduce ventilation duration, and improve patient outcomes. The company targets a significant unmet need in the $2B+ mechanical ventilation weaning market, where prolonged ventilation is associated with increased morbidity, mortality, and healthcare costs. Founded in 2009, Lungpacer has developed a strong intellectual property portfolio and has conducted early clinical studies demonstrating safety and efficacy signals. The AeroPace System has received FDA Breakthrough Device designation, positioning it for expedited regulatory review. Lungpacer is currently preparing for a pivotal clinical trial to support Premarket Approval (PMA) submission. If successful, the device could become the first temporary transvenous diaphragm pacing system cleared for weaning in the United States. With a focused strategy on the ICU setting and a growing body of clinical evidence, Lungpacer represents a compelling opportunity in respiratory medical devices. Key risks include regulatory hurdles, clinical trial enrollment challenges, and competition from alternative weaning technologies.

Upcoming Catalysts (preview)

• Q4 2026FDA Premarket Approval (PMA) Submission for AeroPace System65% success
• Q3 2026Pivotal Clinical Trial Results Publication80% success
• Q2 2026Strategic Partnership for US Commercialization50% success